Traxlink PB 600 Tablet contains Tranexamic Acid 500 mg (Sustained Release) and Pine Bark Extract 100 mg, a specialized combination formulated to help manage excessive bleeding while providing enhanced antioxidant and vascular support. The sustained-release formulation of Tranexamic Acid helps maintain effective therapeutic concentrations over an extended duration, while the higher strength of Pine Bark Extract contributes additional support for healthy blood vessels and microcirculation. The medicine is prescribed under medical supervision for conditions associated with abnormal bleeding.
Tranexamic Acid acts by inhibiting the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and helping stabilize blood clots to control excessive bleeding. The sustained-release formulation provides prolonged antifibrinolytic activity for consistent therapeutic benefit. Pine Bark Extract is a rich source of procyanidins and natural antioxidants that help support vascular integrity, promote healthy circulation, and protect tissues from oxidative stress. Together, these ingredients provide a comprehensive approach to bleeding management and vascular health.
The tablet is commonly prescribed for heavy menstrual bleeding (menorrhagia), gynecological bleeding disorders, postoperative bleeding, and other conditions requiring antifibrinolytic therapy as advised by a healthcare professional. Appropriate use may help reduce blood loss, improve patient comfort, and support overall treatment outcomes. The dosage and duration of treatment should always be individualized according to the patient's clinical condition and physician's recommendations.
With the increasing demand for advanced hemostatic therapies and supportive vascular health solutions, Traxlink PB 600 Tablet maintains strong relevance in the gynecology and hematology segments. Its sustained-release formulation, higher antioxidant support, physician confidence, and broad clinical utility contribute to sustained market demand. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the pharmaceutical hemostatic sector.